114 related articles for article (PubMed ID: 22883451)
1. [Intravesical anchoring of streptavidin-tagged interleukin-4 fusion protein for immunotherapy of mouse superficial bladder cancer].
Zhang Z; Xu XL; Ma L; Li JL; Hu ZM; Gao JM
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):331-5. PubMed ID: 22883451
[TBL] [Abstract][Full Text] [Related]
2. [Immobilization of streptavidin-tagged bioactive hTNF-alpha on biotinylated mucosal surface of the bladder wall for treatment of superficial bladder cancer in mice].
Chen Z; Tan WL; Huang X; Liang ZK; Xu CX; Gao JM
Nan Fang Yi Ke Da Xue Xue Bao; 2010 May; 30(5):936-40. PubMed ID: 20501361
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic potential of SA-sCD40L in the orthotopic model of superficial bladder cancer.
Zhang Z; Xu X; Zhang X; Chen X; Chen Q; Dong L; Hu Z; Li J; Gao J
Acta Oncol; 2011 Oct; 50(7):1111-8. PubMed ID: 21247263
[TBL] [Abstract][Full Text] [Related]
4. A novel immunotherapy for superficial bladder cancer by the immobilization of streptavidin-tagged bioactive IL-2 on the biotinylated mucosal surface of the bladder wall.
Huang X; Yu HS; Chen Z; Li JL; Hu ZM; Gao JM
Chin J Cancer; 2010 Jun; 29(6):611-6. PubMed ID: 20507734
[TBL] [Abstract][Full Text] [Related]
5. A novel immunotherapy for superficial bladder cancer by intravesical immobilization of GM-CSF.
Hu Z; Tan W; Zhang L; Liang Z; Xu C; Su H; Lu J; Gao J
J Cell Mol Med; 2010 Jun; 14(6B):1836-44. PubMed ID: 19627402
[TBL] [Abstract][Full Text] [Related]
6. Sequential administration of GM-CSF and IL-2 surface-modified MB49 cells vaccines against the metastatic bladder cancer.
Shi X; Zhang X; Li J; Guo F; Hu Z; Jing Y; Bai L; Chen S; Wan P; Wang F; Gao J; Tan W
Urol Oncol; 2013 Aug; 31(6):883-93. PubMed ID: 21924648
[TBL] [Abstract][Full Text] [Related]
7. Novel immunotherapy for metastatic bladder cancer using vaccine of human interleukin-2 surface-modified MB 49 cells.
Zhang X; Shi X; Li J; Hu Z; Guo F; Huang X; Zhang Z; Sun P; Jing Y; Gao J; Tan W
Urology; 2011 Sep; 78(3):722.e1-722.e6. PubMed ID: 21741685
[TBL] [Abstract][Full Text] [Related]
8. A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer.
Zhang X; Shi X; Li J; Hu Z; Zhou D; Gao J; Tan W
J Urol; 2012 Mar; 187(3):1071-9. PubMed ID: 22266013
[TBL] [Abstract][Full Text] [Related]
9. Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer.
Sänger C; Busche A; Bentien G; Spallek R; Jonas F; Böhle A; Singh M; Brandau S
BMC Cancer; 2004 Nov; 4():86. PubMed ID: 15566565
[TBL] [Abstract][Full Text] [Related]
10. [Interleukin-21 surface-modified MB49 cell vaccine for treatment of metastatic bladder in mice].
Peng J; Shi X; Chen D; Liang Z; Lan K; Gao J; Tan W
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Jun; 32(6):807-11. PubMed ID: 22699059
[TBL] [Abstract][Full Text] [Related]
11. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model.
Horiguchi Y; Larchian WA; Kaplinsky R; Fair WR; Heston WD
Gene Ther; 2000 May; 7(10):844-51. PubMed ID: 10845722
[TBL] [Abstract][Full Text] [Related]
12. Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49).
Günther JH; Frambach M; Deinert I; Brandau S; Jocham D; Böhle A
J Urol; 1999 May; 161(5):1702-6. PubMed ID: 10210443
[TBL] [Abstract][Full Text] [Related]
13. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
[TBL] [Abstract][Full Text] [Related]
14. Nonviral cytokine gene therapy on an orthotopic bladder cancer model.
Wu Q; Mahendran R; Esuvaranathan K
Clin Cancer Res; 2003 Oct; 9(12):4522-8. PubMed ID: 14555526
[TBL] [Abstract][Full Text] [Related]
15. Intravesical interleukin-15 gene therapy in an orthotopic bladder cancer model.
Matsumoto K; Kikuchi E; Horinaga M; Takeda T; Miyajima A; Nakagawa K; Oya M
Hum Gene Ther; 2011 Nov; 22(11):1423-32. PubMed ID: 21554107
[TBL] [Abstract][Full Text] [Related]
16. Development of a therapy against metastatic bladder cancer using an interleukin-2 surface-modified MB49 bladder cancer stem cells vaccine.
Zhu YT; Pang SY; Lei CY; Luo Y; Chu QJ; Tan WL
Stem Cell Res Ther; 2015 Nov; 6():224. PubMed ID: 26566931
[TBL] [Abstract][Full Text] [Related]
17. New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin.
Kawano H; Komaba S; Yamasaki T; Maeda M; Kimura Y; Maeda A; Kaneda Y
Cancer Chemother Pharmacol; 2008 May; 61(6):973-8. PubMed ID: 17653716
[TBL] [Abstract][Full Text] [Related]
18. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model.
Horinaga M; Harsch KM; Fukuyama R; Heston W; Larchian W
Urology; 2005 Aug; 66(2):461-6. PubMed ID: 16040105
[TBL] [Abstract][Full Text] [Related]
19. Intravesical chitosan/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancer.
Smith SG; Koppolu BP; Ravindranathan S; Kurtz SL; Yang L; Katz MD; Zaharoff DA
Cancer Immunol Immunother; 2015 Jun; 64(6):689-96. PubMed ID: 25754122
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity.
O'Donnell MA; Luo Y; Hunter SE; Chen X; Hayes LL; Clinton SK
J Urol; 2004 Mar; 171(3):1330-5. PubMed ID: 14767343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]